cad-1883
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2018 (NCT03688685)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Intermediate conductance calcium-activated potassium channel protein 4POSITIVE ALLOSTERIC MODULATOR
KCNN4 positive allosteric modulator
- Small conductance calcium-activated potassium channel protein 2POSITIVE ALLOSTERIC MODULATOR
KCNN2 positive allosteric modulator
- Small conductance calcium-activated potassium channel protein 3POSITIVE ALLOSTERIC MODULATOR
KCNN3 positive allosteric modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04301284 | Phase 2 | Aug 31, 2020 | Cadent Therapeutics |
| NCT03688685 | Phase 2 | Nov 30, 2018 | Cadent Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cadent Therapeutics | For profit | 2 | 2 | 1 | 2018 |
1 organizations
Page 1 / 1